At Pfizer Oncology, we are committed to “Outdo Cancer” by advancing transformative medicines wherever we can make a profound difference in the lives of patients. Today, Pfizer Oncology has an industry-leading pipeline that includes the combined legacy Pfizer and Seagen portfolio across breast, genitourinary, hematology-oncology and thoracic therapeutic areas. Thoracic represents a crucial component to achieve Pfizer’s overarching strategic ambition in Oncology; thoracic is estimated to represent ~25% of Pfizer Oncology’s 2030 global sales. Despite therapeutic advances in lung cancer, there remains significant unmet patient need. Each year, there are over 2.5 million new lung cancer diagnoses globally. The lung cancer therapies market is expected to grow from $45B in 2025 to $70B in 2030 globally. Collectively, our focus is on building upon our foundation in lung precision medicine to accelerate new standards of care in broader populations. Pfizer’s lung cancer portfolio is well-positioned to leverage the potential clinical synergy between vedotin antibody drug conjugates (ADCs) and checkpoint inhibitors and to differentiate with novel combination therapies. In July 2025, Pfizer completed the global, ex-China, licensing agreement with 3SBo, Inc. granting Pfizer exclusive rights for the development, manufacturing and commercialization of 3SBio’s SSGJ-707, a bispecific antibody targeting PD-1 and VEGF developed using 3SBio’s proprietary CLF2 platform. SSGJ-707 or PF’4404 aims to displace standard of care PD-1/L1 and VEGF therapies. Several key Phase 3 trial study starts were achieved in 2025, Phase 3 1L squamous and non-squamous NSCLC, Phase 2 / 3 1L ES-SCLC and Phase 3 1L mCRC. This role provides an excellent opportunity to shape the 4404 commercial potential. In Global Marketing, we translate science into value for patients. Our remit is to own the strategic direction across the asset lifecycle, ensure long-term value creation and preservation, and drive brand consistency across markets and efficiencies in execution. This role will report to the Vice President, Global Franchise Lead for Hematology, Thoracic and Gastrointestinal.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Mid Level